COYA
Price
$4.19
Change
+$0.11 (+2.70%)
Updated
Jul 31 closing price
Capitalization
98.29M
15 days until earnings call
Intraday BUY SELL Signals
KNSA
Price
$73.61
Change
-$0.73 (-0.98%)
Updated
Aug 3, 12:19 PM (EDT)
Capitalization
5.8B
92 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

COYA vs KNSA

COYA vs KNSA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
COYA vs. KNSA commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COYA is a Buy and KNSA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 03, 2026
Stock price -- (COYA: $4.19 vs. KNSA: $74.34)
Brand notoriety: COYA and KNSA are both not notable
COYA represents the Biotechnology, while KNSA is part of the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: COYA: 73% vs. KNSA: 86%
Market capitalization -- COYA: $98.29M vs. KNSA: $5.8B
COYA [@Biotechnology] is valued at $98.29M. KNSA’s [@Pharmaceuticals: Generic] market capitalization is $5.8B. The market cap for tickers in the [@Biotechnology] industry ranges from $121.09B to $0. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COYA’s FA Score shows that 1 FA rating(s) are green whileKNSA’s FA Score has 1 green FA rating(s).

  • COYA’s FA Score: 1 green, 4 red.
  • KNSA’s FA Score: 1 green, 4 red.
According to our system of comparison, KNSA is a better buy in the long-term than COYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COYA’s TA Score shows that 3 TA indicator(s) are bullish while KNSA’s TA Score has 4 bullish TA indicator(s).

  • COYA’s TA Score: 3 bullish, 7 bearish.
  • KNSA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, KNSA is a better buy in the short-term than COYA.

Price Growth

COYA (@Biotechnology) experienced а -1.41% price change this week, while KNSA (@Pharmaceuticals: Generic) price change was +18.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.22%. For the same industry, the average monthly price growth was -8.12%, and the average quarterly price growth was +2790.29%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.96%. For the same industry, the average monthly price growth was -4.91%, and the average quarterly price growth was +21.31%.

Reported Earning Dates

COYA is expected to report earnings on Aug 18, 2026.

KNSA is expected to report earnings on Nov 03, 2026.

Industries' Descriptions

@Biotechnology (-1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Generic (+2.96% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KNSA($5.8B) has a higher market cap than COYA($98.3M). KNSA YTD gains are higher at: 80.218 vs. COYA (-27.759). KNSA has higher annual earnings (EBITDA): 102M vs. COYA (-22.5M). KNSA has more cash in the bank: 526M vs. COYA (50.7M). KNSA has higher revenues than COYA: KNSA (841M) vs COYA (7.94M).
COYAKNSACOYA / KNSA
Capitalization98.3M5.8B2%
EBITDA-22.5M102M-22%
Gain YTD-27.75980.218-35%
P/E RatioN/A75.09-
Revenue7.94M841M1%
Total Cash50.7M526M10%
Total DebtN/A8.9M-
FUNDAMENTALS RATINGS
KNSA: Fundamental Ratings
KNSA
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
PROFIT vs RISK RATING
1..100
3
SMR RATING
1..100
60
PRICE GROWTH RATING
1..100
35
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
29

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
COYAKNSA
RSI
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
88%
Bearish Trend 4 days ago
74%
Momentum
ODDS (%)
Bearish Trend 4 days ago
78%
Bullish Trend 4 days ago
84%
MACD
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
80%
Bullish Trend 4 days ago
81%
Advances
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 6 days ago
77%
Declines
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 4 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 4 days ago
76%
Aroon
ODDS (%)
Bearish Trend 4 days ago
61%
Bullish Trend 4 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
COYA
Daily Signal:
Gain/Loss:
KNSA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
REK15.350.08
+0.52%
ProShares Short Real Estate
IBHJ26.330.04
+0.15%
iShares iBonds 2030 Term Hi Yld & IncETF
VOXP38.13N/A
N/A
Vox Populi ETF
VBR244.63-0.48
-0.20%
Vanguard Morn Small Cap Value ETF
RMT13.62-0.08
-0.58%
Royce Micro-Cap Trust

COYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, COYA has been loosely correlated with GANX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if COYA jumps, then GANX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COYA
1D Price
Change %
COYA100%
+2.70%
GANX - COYA
42%
Loosely correlated
-4.55%
KNSA - COYA
42%
Loosely correlated
-4.94%
VIR - COYA
38%
Loosely correlated
-2.70%
RCKT - COYA
37%
Loosely correlated
-3.12%
EDIT - COYA
35%
Loosely correlated
-4.09%
More